Peak et al. [52] demonstrated significantly shorter progression-free survival (PFS) among advanced ovarian cancer patients with elevated HE4 at OC diagnosis, compared to patients with non-elevated HE4 levels (20.1 vs. 24.2 months, p = 0.029). The gene discussed is WFDC2; the disease is ovarian cancer.